Prossnitz, Eric R. http://orcid.org/0000-0001-9190-8302
Barton, Matthias http://orcid.org/0000-0002-8200-4341
Article History
Accepted: 28 February 2023
First Online: 16 May 2023
Competing interests
: M.B. and E.R.P. are inventors on U.S. patent Nos. 10,251,870, 10,682,341 and 10,980,785, and E.R.P. is an inventor on U.S. Patent Nos. 10,471,047 and 10,561,648, all for the therapeutic use of compounds targeting GPER (“Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER”). E.R.P. is an inventor on U.S. Patent Nos. 7,875,721 and 8,487,100 for GPER-selective ligands and imaging agents (“Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof”). M.B. has served or serves as a consultant to Abbott, Inc., Abbvie, Inc., Travere, Inc. and Pharmazz, Inc.
Free to read: This content has been made available to all.